Puma Biotechnology Inc. (PBYI) Receives “Buy” Rating from Stifel Nicolaus
Puma Biotechnology Inc. (NYSE:PBYI)‘s stock had its “buy” rating reaffirmed by equities research analysts at Stifel Nicolaus in a research note issued on Wednesday. They presently have a $88.00 target price on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 104.41% from the company’s current price.
Other equities research analysts also recently issued reports about the company. Cowen and Company restated a “market perform” rating on shares of Puma Biotechnology in a research report on Tuesday, November 15th. Credit Suisse Group AG restated an “outperform” rating and set a $111.00 price objective on shares of Puma Biotechnology in a research report on Tuesday, November 15th. Vetr downgraded Puma Biotechnology from a “strong-buy” rating to a “strong sell” rating and set a $39.50 price objective on the stock. in a research report on Wednesday, August 10th. JPMorgan Chase & Co. set a $89.00 price objective on Puma Biotechnology and gave the company a “buy” rating in a research report on Monday, November 14th. Finally, Citigroup Inc. set a $88.00 price objective on Puma Biotechnology and gave the company a “buy” rating in a research report on Monday, November 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $68.56.
Puma Biotechnology (NYSE:PBYI) traded down 4.23% on Wednesday, hitting $43.05. The stock had a trading volume of 483,518 shares. The firm’s market capitalization is $1.59 billion. The stock’s 50-day moving average is $44.60 and its 200 day moving average is $45.34. Puma Biotechnology has a 1-year low of $19.74 and a 1-year high of $82.81.
ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc. (PBYI) Receives “Buy” Rating from Stifel Nicolaus” was first published by Daily Political and is the propert of of Daily Political. If you are reading this news story on another website, it was illegally copied and reposted in violation of United States & international copyright law. The correct version of this news story can be read at http://www.dailypolitical.com/2016/11/30/puma-biotechnology-inc-pbyi-receives-buy-rating-from-stifel-nicolaus.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in PBYI. BNP Paribas Arbitrage SA boosted its position in shares of Puma Biotechnology by 112.0% in the third quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 1,127 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 1,740 shares during the period. Prudential Financial Inc. purchased a new position in shares of Puma Biotechnology during the third quarter valued at about $201,000. Ardsley Advisory Partners purchased a new position in shares of Puma Biotechnology during the third quarter valued at about $201,000. Finally, Laurion Capital Management LP purchased a new position in shares of Puma Biotechnology during the third quarter valued at about $208,000. 80.98% of the stock is currently owned by institutional investors.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.
Receive News & Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.